This is an aggregated industry headline. Read the full story at FiercePharma →
The Oral GLP-1 Tracker: Novo's oral Wegovy hits 3M prescription milestone as Lilly's Foundayo chugs along in early launch
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts' notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
By FiercePharma
· Jun 9, 2026
· via FiercePharma
Image: FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
An FDA advisory committee has recommended that four peptide drugs that were previously restricted because of p…
The WeekFierceBiotech ↗
Sanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once t…
The WeekDrug Channels ↗
Today's guest post comes from Chip Parkinson, CEO at Gifthealth. Chip discusses how Direct-to-Patient (DTP) mo…